SHANGPHARMA CORP (SHP) IPO - NASDAQ.com
Company IPO Overview
SHANGPHARMA CORP (SHP) IPO
The IPO profiles may contain historical records.
Please visit the
for the most recent information.
Company Name
SHANGPHARMA CORP
Company Address
NO. 5 BUILDING, 998 HALEI ROADZHANGJIANG HI-TECH PARK PUDONG NEW AREASHANGHAI 201203
Company Phone
Company Website
Michael Xin Hui
(as of 6/30/2010)
State of Inc
Fiscal Year End
Priced (10/19/2010)
Proposed Symbol
Share Price
Shares Offered
Offer Amount
$87,000,000.00
Total Expenses
$3,649,447.00
Shares Over Alloted
Shareholder Shares Offered
Shares Outstanding
335,600,000
Lockup Period (days)
Lockup Expiration
Quiet Period Expiration
11/29/2010
Company Description
We are a leading China-based pharmaceutical and biotechnology research and
development, or R&D, outsourcing company. We provide a broad range of high-
quality, integrated services across the drug discovery and development process
to international and Chinese pharmaceutical and biotechnology
companies. Our
services consist of discovery chemistry, discovery biology and preclinical
development, pharmaceutical development and biologics services. We offer our
services on a full-time-equivalent, or FTE, basis or a fee-for-service basis.
Capitalizing on our broad service offerings, the experience and expertise of
our skilled scientists and our state-of-the-art facilities and equipment, we
help our customers discover and develop novel drug candidates efficiently. We
have a diversified and loyal global customer base. We provide services to over
100 customers, including all of the top ten pharmaceutical and biotechnology
companies in the world in terms of 2009 revenues ranked by Frost & Sullivan and
a number of fast-growing biotechnology and specialty pharmaceutical companies,
as well as renowned academic and research institutions in the U.S. and China.
Most of our customers return to us for additional and often larger projects,
and all of our top ten customers in each of 2008 and 2009 remain our customers
Our experienced and strong R&D team contributes significantly to our market
leadership. We have successfully grown our scientific research staff from 988
as of December 31, 2007 to 1,525 as of June 30, 2010. Over 60% of our
scientific research staff have post-graduate degrees, including many native
Chinese scientists and managers who have returned to China after studying or
working overseas with experience in global pharmaceutical and biotechnology
companies and knowledge of Western business practices. These Western-educated
native Chinese who have returned to China are commonly referred to as
returnees. Based in China and headquartered in Shanghai, we are well-positioned
to attract a large number of returnees and benefit from an abundant supply of
highly skilled, domestically-trained scientific talent in China. We attract,
retain and motivate our employees through a comprehensive training and career
development program and equity incentive plans.
We conduct our laboratory activities in four primary facilities in China: (i)
an approximately 450,000 square-foot laboratory and headquarters in Shanghai
Zhangjiang Hi-Tech P (ii) an approximately 13,000 square-foot AAALAC-
accredited animal facility in Shanghai Zhangjiang Hi-Tech P (iii) an
approximately 36,000 square-foot R&D center in C and (iv) an
approximately 28,000 square-foot manufacturing facility in Nanhui, Shanghai. In
addition, we are constructing an approximately 460,000 square-foot cGMP-quality
multi-purpose manufacturing facility in Fengxian, Shanghai, designed to
manufacture advanced intermediates and active pharmaceutical ingredients, or
APIs, for preclinical testing and clinical trials. We are also constructing an
approximately 150,000 square-foot laboratory services building in Fengxian,
Shanghai primarily for pharmaceutical development services. Our strategic
location in China provides us many advantages, including relatively low-cost
labor, developed infrastructure and favorable government incentives as well as
a large talent pool.
We have experienced significant growth in recent years. Our net revenues
increased from $34.7 million in 2007 to $60.5 million in 2008 and $72.3 million
in 2009, representing a compound annual growth rate, or CAGR, of 44.4%, and
increased by 27.2% from $32.7 million in the six months ended June 30, 2009 to
$41.6 million in the six months ended June 30, 2010. The number of our
customers increased from 71 in 2007 to 99 in
in 2009 and 151 in the
six months ended June 30, 2010. Our net income increased from $7.5 million in
2007 to $9.1 million in 2008 and $9.8 million in 2009, and increased from $4.6
million in the six months ended June 30, 2009 to $6.9 million in the six months
ended June 30, 2010.
and the nine months ended September 30, 2010, our founders
granted restricted share units, or RSUs, convertible to 7,450,000, 2,100,000
and 2,200,000 ordinary shares, respectively, to certain members of our senior
management and other employees under the Founder’s 2008 Equity and Performance
Incentive Plan, or the Founder’s Plan. We have not recorded any share-based
compensation expense in connection with these RSU grants because one of the
vesting conditions for the RSUs is the completion of our initial public
offering. As a result, upon completion of this offering, we expect to incur a
significant share-based compensation charge of approximately $2.5 million,
which will materially and adversely affect our results of operations for the
quarter in which this offering is completed.
Our principal executive offices are located at No. 5 Building, 998 Halei Road,
Zhangjiang Hi-Tech Park Pudong New Area, Shanghai, 201203, People’s Republic
of China. Our telephone number at this address is (86-21) . Our
registered office in the Cayman Islands is located at Cricket Square, Hutchins
Drive, P.O. Box 2681, Grand Cayman, KY1-1111, Cayman Islands. Our main website
is www.shangpharma.com. Our agent for service of process in the United States
is Law Debenture Corporate Services Inc. located at 400 Madison Avenue, 4th
Floor, New York, New York 10017.
Powered by:EDGAR® Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.
Total Liabilities
$16,825,937
Stockholders' Equity
$27,582,698
Company Filings
Viewing: 1 - 6 Total: 6
Company Name
Date Received
SHANGPHARMA CORP
10/19/2010
SHANGPHARMA CORP
10/15/2010
SHANGPHARMA CORP
10/13/2010
SHANGPHARMA CORP
SHANGPHARMA CORP
SHANGPHARMA CORP
9/18/:00 PM - Seeking Alpha
1/21/:00 AM - Seeking Alpha
12/27/:00 AM - Seeking Alpha
12/23/:00 AM - Seeking Alpha
2/5/:00 AM - Seeking Alpha
Latest News Headlines
11:40PM ET& - GlobeNewswire
9:00PM ET& - GlobeNewswire
5:46PM ET& - Reuters
5:16PM ET& - GlobeNewswire
Expected Report Date
Edit Favorites
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
&Slate Gray
&Light Gray
&Gray Blue
Quote Search
Select a default target page for your quote search:
&Real-Time
&After Hours
&Pre-Market
&Flash Quote
&Summary Quote
&Interactive Charts
&Default Setting
Please note that once you make your selection, it will apply to all future visits to NASDAQ.com.
If, at any time, you are interested in reverting to our default settings, please select Default Setting above.
If you have any questions or encounter any issues in changing your default settings, please email .
Please confirm your selection:
You have selected to change your default setting for the Quote Search. This will now be your
unless you change your configuration again, or you delete your
cookies. Are you sure you want to change your settings?
Please disable your ad blocker (or
to ensure that javascript and cookies are enabled), so that we can continue to provide you with the first-rate market news and data you've come to expect from us.当前位置： &
& > & 我叫MT修改REBUG（rogero）教程详解
我叫MT修改REBUG（rogero）教程详解
类别：&&大小：105.58MB语言：简体中文&&
　　　 &小编力荐： &我叫MT修改REBUG(rogero)教程详解。想使用rebug版的我叫MT手游，就需要先下载下面两个文件：　　1、点击下载：烧饼修改器软件名称：烧饼游戏修改器软件大小：976KB下载地址：　　2、点击下载：我叫MT安卓破解版软件名称：我叫MTv3.5.4安卓破解版软件大小：106MB下载地址：　　安装完下载下来的两个文件后。安装过程就不说明了。　　　　接下来跟着步骤走：　　1、打开烧饼修改器　　2、打开我叫MT游戏，然后接下来这一步很关键!在点击“点击进入游戏”的一瞬间点击“烧饼修改器”然后进入下面画面。　　　　3、填自己的ID点击搜索(自己的ID可以在游戏里面的好友邀请可以查到)　　4、修改ID为 　　5、确认下面两排ID为　　6、把两排ID前的锁头都锁上　　　　然后就可以使用我叫MT破解rebug版的功能了!　　格子啦小编推荐：　　我叫MT 破解版：　　我叫MT官方版：　　我叫mt苹果版：
　　更多尽在格子啦安卓频道。
负责频道：资讯
关于本文的作者
上一篇 &：
下一篇 &：
文章链接：//www.gezila.com/raiders/12394.html
(转载时请注明本文出处及文章链接)查看: 1527|回复: 0
rogero 4.55 能直接升rebug4.65吗？
猥币203416
在线时间425 小时
阅读权限50
帖子猥币巴士票
猥言大义 Lv.5, 积分 1291, 距离下一级还需 709 积分
rogero不给力啊，等的花儿都谢了，想升rebug4.65,不知道能直接升吗
Powered byPS3 rogero 4.55 怎么刷成 rebug 4.7-3系统是rogero 4.55的， _快递评论网
你的位置：& > &
PS3 rogero 4.55 怎么刷成 rebug 4.7
PS3 rogero 4.55 怎么刷成 rebug 4.7
70.1 D-REX EDITION，请问这个系统怎么样，能不能刷，具体要怎么做？ 还有如果不升级系统.55.00。3月份出了 REBUG 4。想要把机器全部格式化以后，重新装游戏，最好顺带升级系统，2512软破机我现在用的是 rogero 4.55 ，multiMAN版本04
UPDATE 下，并将名称改为PS3UPDAT，拷贝到U盘的PS3&#47下载破解版rebug4.70系统.PUP
下载一个安装包就ok，但是网络上面下载的一般会带有病毒，请你去专业的店铺里面找专人为你更新
你可能感兴趣的内容？Mobile Site